Eukedos S.p.A. (IT:EUK)
:EUK
Top Page
Eukedos S.p.A.
(EUK)
Select Model
Select Model
Rating:54Neutral
Price Target:
€0.69
▼(-4.31% Downside)
Action:ReiteratedDate:10/31/25
Eukedos S.p.A. shows strong operational efficiency, but financial risks due to high leverage and cash flow issues are significant concerns. Technical indicators suggest a stable outlook, but valuation metrics are unfavorable due to negative profitability. The absence of earnings call data and corporate events limits further insights.
Positive Factors
High gross & EBITDA margins
Extremely high gross margin and healthy EBITDA margin indicate durable cost advantages and pricing power in Eukedos' product mix. This margin structure supports reinvestment in R&D and product development, enabling sustained competitiveness across sectors over months.
Negative Factors
High financial leverage
A debt-to-equity ratio above 3x materially increases interest and refinancing risk, constraining strategic flexibility. With elevated leverage, the company faces durable pressure on cash flow allocation, limiting ability to fund growth or absorb shocks without external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross & EBITDA margins
Extremely high gross margin and healthy EBITDA margin indicate durable cost advantages and pricing power in Eukedos' product mix. This margin structure supports reinvestment in R&D and product development, enabling sustained competitiveness across sectors over months.
Read all positive factors
Eukedos S.p.A. (EUK) vs. iShares MSCI Italy ETF (EWI)
Market Cap
€12.05M
Dividend YieldN/A
Average Volume (3M)4.68K
Price to Earnings (P/E)―
Beta (1Y)0.15
Revenue Growth4.81%
EPS Growth-260.95%
CountryIT
Employees483
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)N/A
Shares Outstanding22,741,629
10 Day Avg. Volume3,064
30 Day Avg. Volume4,678
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)0.62
Price to Sales (P/S)0.36
P/FCF Ratio-1.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Eukedos S.p.A. Business Overview & Revenue Model
Company Description
EuKedos S.p.A. provides managed and long-term care services in Italy. The company offers residential social care services to elderly, self-sufficient, or incapacitated adults. It manages healthcare and assistance residences with 1,345 beds in the ...
How the Company Makes Money
Eukedos generates revenue primarily through the sale of its biochemical products across multiple sectors. The company's revenue model is based on direct sales to businesses in the pharmaceutical and agricultural industries, as well as partnerships...
Eukedos S.p.A. Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 52.60M | 51.69M | 49.45M | 47.04M | 45.18M | 46.99M |
| Gross Profit | 13.25M | 48.96M | 13.73M | 32.03M | 32.99M | 33.77M |
| EBITDA | 7.95M | 12.27M | 12.41M | 10.87M | 10.72M | 7.63M |
| Net Income | -1.15M | -524.00K | 556.00K | 443.00K | 570.00K | -1.92M |
Balance Sheet | ||||||
| Total Assets | 178.40M | 179.34M | 149.10M | 153.38M | 150.08M | 146.26M |
| Cash, Cash Equivalents and Short-Term Investments | 2.68M | 3.91M | 2.33M | 3.62M | 7.39M | 2.64M |
| Total Debt | 124.82M | 99.02M | 105.83M | 111.45M | 108.95M | 102.89M |
| Total Liabilities | 149.35M | 149.50M | 119.19M | 123.99M | 121.26M | 118.02M |
| Stockholders Equity | 29.05M | 29.84M | 29.91M | 29.39M | 28.82M | 28.25M |
Cash Flow | ||||||
| Free Cash Flow | -15.15M | -13.14M | 3.59M | 1.03M | 5.31M | 1.27M |
| Operating Cash Flow | 5.81M | 9.94M | 10.08M | 5.18M | 5.61M | 6.68M |
| Investing Cash Flow | -50.70M | -58.49M | -8.92M | -4.15M | -306.00K | -5.31M |
| Financing Cash Flow | 42.76M | 50.13M | -2.45M | -4.79M | -562.00K | -1.71M |
Eukedos S.p.A. Technical Analysis
Negative
0.72
Price Trends
0.64
Negative
0.68
Negative
0.71
Negative
Market Momentum
-0.04
Positive
36.13
Neutral
37.83
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:EUK, the sentiment is Negative. The current price of 0.72 is above the 20-day moving average (MA) of 0.57, above the 50-day MA of 0.64, and above the 200-day MA of 0.71, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 36.13 is Neutral, neither overbought nor oversold. The STOCH value of 37.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IT:EUK.
Eukedos S.p.A. Peers Comparison
UnderperformOutperform
Sector (51)
IT:EUK
Eukedos S.p.A.
0.53
-0.22
-29.33%
IT:ARBS
Arterra Bioscience SpA
3.05
1.07
54.04%
IT:COSMO
Farmacosmo S.P.A.
0.49
-0.21
-30.57%
IT:TALEA
Farmae SpA
4.80
0.61
14.56%
IT:ERFO
Laboratorio Farmaceutico Erfo SpA
1.12
0.01
1.36%
IT:SVS
Svas Biosana S.p.A.
8.42
1.61
23.64%
Eukedos S.p.A. Corporate Events
Eukedos S.p.A. Aligns 2024 Sustainability Report with EU Taxonomy
Dec 1, 2025
Eukedos S.p.A. has clarified its 2024 Sustainability Report in line with EU Taxonomy regulations, which classify eco-sustainable economic activities. The company identified its residential care services and energy efficiency projects as eligible a...
Eukedos S.p.A. Announces 2026 Corporate Event Calendar
Nov 10, 2025
Eukedos S.p.A. has announced its corporate event calendar for 2026, highlighting key dates for financial disclosures and shareholder meetings. This schedule outlines the company’s commitment to transparency and regular communication with sta...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.